Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M0XB
|
|||
| Former ID |
DCL000368
|
|||
| Drug Name |
Saracatinib
|
|||
| Synonyms |
H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hematologic tumour [ICD-11: 2B33.Y] | Phase 2 | [1], [2] | |
| Osteosarcoma [ICD-11: 2B51] | Phase 2 | [1], [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 2 | [1], [2] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H32ClN5O5
|
|||
| Canonical SMILES |
CN1CCN(CC1)CCOC2=CC3=C(C(=C2)OC4CCOCC4)C(=NC=N3)NC5=C(C=CC6=C5OCO6)Cl
|
|||
| InChI |
1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)
|
|||
| InChIKey |
OUKYUETWWIPKQR-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 379231-04-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
15309164, 17422546, 21317858, 22676280, 41368296, 46394234, 46512739, 50076463, 52589432, 57374518, 85197643, 85246182, 92721419, 99431771, 103501598, 109692957, 118844934, 124490404, 124756929, 124950158, 125163736, 125349317, 126619163, 126660092, 126666998, 131312788, 131465100, 134339018, 134344133, 135252487, 135686054, 135686055, 135686076, 135686077, 135727436, 136368072, 136920278, 136946508, 137185244, 137275842, 141775073, 144115661, 152258141, 152344117, 160646980, 162011430, 162037380, 162200062, 163884828, 164042932
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7731). | |||
| REF 2 | Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27. | |||
| REF 3 | Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.